Crinetics Pharmaceuticals, Inc. — Director's Dealing 2021

Oct 19, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2021-10-15

Reporting Person: Betz Stephen F. (Chief Scientific Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	187925	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$1.91	2028-03-16	Common Stock (182370)		Direct
Stock Option (right to buy)	$9.28	2028-05-24	Common Stock (91185)		Direct
Stock Option (right to buy)	$25.19	2029-03-07	Common Stock (56250)		Direct
Stock Option (right to buy)	$22.61	2030-02-23	Common Stock (60000)		Direct
Stock Option (right to buy)	$15.29	2031-02-25	Common Stock (85000)		Direct
Stock Option (right to buy)	$23.19	2031-09-09	Common Stock (15000)		Direct

Footnotes

F1: 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person.

F2: 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date; provided, however, that one-half of the shares subject to the option are subject to the further condition that they may not be exercised until the occurrence of the Issuer's initial public offering and, in the event the Issuer's initial public offering does not occur prior to the first anniversary of May 25, 2018, such portion of the stock options shall be automatically forfeited. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person.

F3: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement Date of March 8, 2019.

F4: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 24, 2020.

F5: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 26, 2021.

F6: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of September 1, 2021.